World’s First “Reverse Aging” Gene Therapy Completes First Human Injection
Release time:
2026-06-12
On June 9, 2026, Life Biosciences, a biotechnology company based in Boston, USA, announced that the world’s first gene therapy aimed at “reversing cellular aging” has been administered to its first human patient. The goal of this clinical trial is to “rejuvenate” cells whose function has deteriorated due to aging by activating three key genes, thereby treating open-angle glaucoma, an age-related eye disease that can lead to blindness.
From Nobel Prize to “Partial Reprogramming”
The theoretical foundation of this therapy dates back to 2006, when Japanese scientist Shinya Yamanaka discovered that simultaneous activation of four transcription factors—Oct4, Sox2, Klf4, and c-Myc (collectively known as OSKM or “Yamanaka factors”)—can reprogram mature somatic cells into pluripotent stem cells, which can then differentiate into any cell type. This breakthrough earned him the 2012 Nobel Prize in Physiology or Medicine.
However, high expression of c-Myc carries a risk of carcinogenesis, limiting its application in humans. To address this, scientists proposed a “partial reprogramming” strategy: activating only three genes—Oct4, Sox2, and Klf4—to restore youthful characteristics without completely erasing cell identity.
In 2020, a team led by David Sinclair at Harvard Medical School published a cover paper in Nature demonstrating that activating these three genes in mice with optic nerve damage promoted neuronal regeneration and reversed vision loss in aged and glaucoma-affected mice.
First Human Trial: Precise, Controllable, Safety-First
This Phase 1 clinical trial, approved by the U.S. FDA in January 2026, targets two age-related vision loss diseases: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The research team uses a modified viral vector to deliver the three genes to retinal ganglion cells in patients, with multiple safety mechanisms in place:
Local administration: Injection into only one eye to reduce systemic risk;
Drug switch: The three genes are expressed only when the patient takes doxycycline; expression ceases when the drug is stopped;
Long-term follow-up: All participants will be monitored for at least five years to assess long-term safety.
Eye disease was chosen as the first application because the eye is relatively isolated, reducing the risk of systemic side effects from gene therapy, and it allows for direct observation of therapeutic effects.
Beyond the Eye: Broad Prospects for Anti-Aging Therapy
In addition to eye diseases, Life Biosciences is exploring the potential of “partial reprogramming” for conditions such as liver fibrosis. If this trial confirms its safety and feasibility, it could open an entirely new path for anti-aging medicine—shifting from passively managing age-related diseases to actively reversing the aging process at the cellular level.
Previous article
Previous article
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
